SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. Vir Biotechnology Inc.(纳斯达克代码:VIR)今天宣布,董事长Marianne De Backer女士将于9月5日星期四下午1:50在纽约市的摩根士丹利第22届全球医疗保健大会上参加一次座谈会。
您可以在Vir网站的“事件与演示”栏目下找到座谈会的实时网络直播,该网站将保留座谈会的存档30天。
关于Vir Biotechnology,Inc。
Vir Biotechnology,Inc.是一家临床阶段的生物制药公司,致力于通过发现和开发治疗严重传染性疾病和癌症的药物来改变生命。Vir的临床阶段投资组合包括用于治疗慢性三角洲型肝炎和慢性乙型肝炎感染的传染病项目,以及多个肿瘤学项目。Vir还拥有一系列其他传染性疾病和肿瘤恶性肿瘤的临床前投资组合。Vir定期在其网站上发布对投资者可能重要的信息。
媒体
高级副总裁Corporate CommunicationsArran Attridge
高级副总裁,企业传讯
aattridge@vir.bio
投资者联系
Richard Lepke
投资者关系高级董事
rlepke@vir.bio
来源:Vir Biotechnology,Inc.